113
Views
3
CrossRef citations to date
0
Altmetric
Review

Lipodystrophy in HIV patients: its challenges and management approaches

&
Pages 135-143 | Published online: 14 Dec 2011

Figures & data

Table 1 Types of lipodystrophy

Figure 1 Computerized tomography scans of (A) a healthy adult and (B) a patient with coexisting lipoatrophy and lipohypertrophy. In comparison with the healthy adult, the patient with coexisting lipoatrophy and lipohypertrophy has less subcutaneous adipose tissue and an increase in intra-abdominal (visceral) adipose tissue.

Figure 1 Computerized tomography scans of (A) a healthy adult and (B) a patient with coexisting lipoatrophy and lipohypertrophy. In comparison with the healthy adult, the patient with coexisting lipoatrophy and lipohypertrophy has less subcutaneous adipose tissue and an increase in intra-abdominal (visceral) adipose tissue.

Table 2 HIV-associated lipodystrophy: epidemiological associations

Figure 2 Change in endothelial function in the AIDS Clinical Trials Group study 5142.Citation32 This study examined a class-sparing strategy and a substudy examined endothelial function as flow-mediated dilatation (FMD). FMD was impaired at baseline and improved during highly active antiretroviral therapy. The improvement was independent of a specific regimen and bore no relationship to baseline viral load; however, it had a significant association with the decrease in viral load.

*Data expressed as percent and presented as absolute change compared with pretreatment values.

Notes: Data as change in flow-mediated diameter, expressed as percent. Within-group differences: P < 0.005 for PI-sp and NNRTI-sp regimens; P = 0.015 for NRTI-sp regimen.
Abbreviations: NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; sp, sparing.
Figure 2 Change in endothelial function in the AIDS Clinical Trials Group study 5142.Citation32 This study examined a class-sparing strategy and a substudy examined endothelial function as flow-mediated dilatation (FMD). FMD was impaired at baseline and improved during highly active antiretroviral therapy. The improvement was independent of a specific regimen and bore no relationship to baseline viral load; however, it had a significant association with the decrease in viral load.*Data expressed as percent and presented as absolute change compared with pretreatment values.